RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma

Hormone Research
D J MarshC Eng

Abstract

Multiple endocrine neoplasia type 2 (MEN-2) is a familial cancer syndrome inherited in an autosomal dominant fashion with age-related penetrance. The main tumour type present in all manifestations of this syndrome. MEN-2A, MEN-2B and familial medullary thyroid carcinoma (FMTC), is medullary thyroid carcinoma (MTC). MTC arises from the parafollicular or C cells of the thyroid. MEN-2A is characterised by the triad of MTC, phaeochromocytoma, and parathyroid hyperplasia. MEN-2B is characterised by features similar to those of MEN-2A, except for the absence of clinically apparent parathyroid hyperplasia, and additional stigmata including a marfanoid habitus, mucosal neuromas and ganglioneuromatosis of the gastrointestinal tract. FMTC families have MTC as their only phenotype. Missense mutations affecting conserved cysteine codons adjacent to the transmembrane domain of the RET proto-oncogene have been identified in the germline DNA of patients with MEN-2A and FMTC. A single mutation at codon 918 in the tyrosine kinase domain of the RET receptor has been associated with the MEN-2B phenotype. In a small number of FMTC families, missense point mutations have also been identified in the intracellular domain of the RET protein. RET mutat...Continue Reading

Citations

Jul 31, 2001·International Journal of Cancer. Journal International Du Cancer·C IribarrenG D Friedman
Jul 26, 2006·Wiener klinische Wochenschrift·Damijan BergantSimon Caserman
Mar 11, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A MemonA Suresh
Aug 15, 2002·Cancer Letters·Deborah Marsh, Roberto Zori
Apr 8, 2010·The Journal of Clinical Endocrinology and Metabolism·Bruce G RobinsonRobert Haddad
Oct 27, 2007·Annals of Surgical Oncology·Curtis J WrayDouglas B Evans
Nov 1, 2007·Expert Opinion on Medical Diagnostics·Deborah J MarshAnthony J Gill
Nov 24, 2006·Clinical Endocrinology·Anne-Paule Gimenez-RoqueploUNKNOWN European Network for the Study of Adrenal Tumours (ENS@T) Pheochromocytoma Working Group
Dec 22, 2004·Arquivos brasileiros de endocrinologia e metabologia·Hans Graf
May 7, 2005·Pathology·Nam Hoon ChoChung Su Park
May 11, 2005·Familial Cancer·Mariola Peczkowska, Andrzej Januszewicz
Jul 2, 2010·The Journal of Clinical Hypertension·Sergio Chang FigueroaJames R Sowers
Feb 18, 2003·Endocrine Reviews·Laszlo HegedüsFinn N Bennedbaek
Apr 8, 2003·The Journal of Clinical Endocrinology and Metabolism·Deborah J MarshBruce G Robinson
Oct 20, 2015·Journal of Pediatric Hematology/oncology·Vidya K NarayananMohamad G Shaikh
Aug 14, 2020·The Journal of Clinical Endocrinology and Metabolism·Alfonso Cordero-BarrealCristina Montero-Conde
Aug 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C Eng
Jan 1, 2008·Biomarker Insights·Rosaria M RuggeriMaria Trovato
Jul 23, 1999·The Medical Journal of Australia·J R Burgess
Apr 7, 2006·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Hossein GharibUNKNOWN AACE/AME Task Force on Thyroid Nodules
Jun 25, 2021·Current Treatment Options in Oncology·Fangdi Sun, Caroline E McCoach

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.